FINEOS Welcomes Allison Morgan as New Senior Sales Executive for North America
FINEOS Corporation (ASX:FCL), the leading core platform for life, accident and health insurance globally, today announces the appointment of Allison Morgan as Senior Sales Executive to the FINEOS North American team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005639/en/
Allison Morgan (Photo: Business Wire)
Allison brings nearly 25 years of proven experience as an accomplished absence and disability sales leader and consultant with powerful relationship building, negotiation, communication and presentation skills. She has a proven track record and demonstrated ability to obtain, grow and retain a customer base to support organizational objectives.
In her new role at FINEOS, Allison will be responsible for developing new business clients for FINEOS Claims, FINEOS Absence and FINEOS AdminSuite. Alison’s expertise in absence management is especially important as Integrated Disability and Absence management (IDAM) becomes a major product offering for insurance carriers serving the Employee Benefits space. She will work closely with brokers, consultants, and complementary product vendors within the Employee Benefits market.
FINEOS AdminSuite is a modern integrated core processing system that consists of absence, claims, payments, billing, policy, and provider administration – all of which are configurable to operate independently or optimally as a full core suite as part of the SaaS delivered FINEOS Platform, powered by AWS.
Prior to joining FINEOS, Allison worked for eight years at Reed Group, a Guardian company, where she was responsible for new business development of absence management software and outsourcing opportunities, focusing on the design of short and long term disability and absence programs for companies with 5,000 employees and above. Previously, she held senior positions in large insurance companies and brokers including MetLife and Aon Hewitt.
“We are delighted to welcome Allison to the FINEOS team and look forward to working closely with her to continue to help insurance carriers in North America realize the benefits of partnering with FINEOS,” said Michael Kelly, CEO, FINEOS. “In addition to having to transform their business to a fully digital model that delivers excellent customer experience, insurers need to provide risk-based products integrated with comprehensive service offerings that include non-traditional products and services, like IDAM. Our 100% commitment to the Employee Benefits market requires experienced people with a strong understanding of the market today and where it is going in the future. Allison brings that next level of focus on IDAM within the Employee Benefits market for FINEOS. We couldn’t be more pleased to have her on board.”
“I am thrilled to join FINEOS, who is known throughout the insurance industry as the leading provider of core technology solutions. As insurers evaluate their current technology, they are recognizing a critical need to effectively and efficiently meet the growing needs of their customers, both employees and employers, who continue to demand a best-in-class product, service and claims experience enabled by modern technology,” said Allison Morgan, senior sales executive for North America. “Additionally, as entitlement laws continue to pass, insurers need state-of-the-art technology solutions to maintain compliance with various federal, state and local laws. FINEOS brings together all of those considerations to create efficient and robust technology solutions enabling the insurer or Third-Party Administrator to focus on better serving their customers and partnering with FINEOS to achieve their growth objectives.”
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005639/en/
Contact information
Victoria Jamison
Marketing Manager
FINEOS Corporation
+ 353 1 639 9767
Victoria.Jamison@FINEOS.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
